Fudan University: Triple Negative Breast Neoplasms trials

The registry lists 66 Triple Negative Breast Neoplasms studies with Fudan University as lead sponsor. 36 are open to participants now and 0 have results posted.

Phase 1 4Phase 2 42Phase 3 17Phase 4 2No phase 4(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Thymalfasin Combined With Chemotherapy and Immunotherapy in TNBC Neoadjuvant TreatmentNot yet recruitingNCT07884201Phase 2
• An Open-Label, Randomized Phase III Study of Trastuzumab Rezetecan With or Without Everolimus in First to Third Line LAR Subtype TNBCNot yet recruitingNCT07760844Phase 3
• Granzyme B-PET: Predicting Immunotherapy Efficacy in TNBCRecruitingNCT07705438
• An Open-Label, Randomized Phase III Study of Trastuzumab Rezetecan With or Without Bevacizumab in First to Third Line BLIS Subtype TNBCNot yet recruitingNCT07669610Phase 3
• Study of Radiotherapy Combined With Cisplatin/Carboplatin, Adebrelimab and Bevacizumab in the Treatment of TNBC-BM.RecruitingNCT07638852Phase 2
• Real-world Patient-reported Outcome of Sacituzumab Govitecan in Chinese Metastatic Breast CancerRecruitingNCT07551050
• QLC5513 Alone or in Combination With QL1706 in Previously Treated Advanced or Metastatic TNBC.Not yet recruitingNCT07509515Phase 2
• Re-challenge Immunotherapy With Cromolyn, TQB2102, and Panpulimab in Immune-Refractory Triple Negative Breast CancerNot yet recruitingNCT07419880Phase 2
• Adjuvant Intensification for LARNot yet recruitingNCT07407517Phase 3
• Neoadjuvant Therapy With Ivonescimab Combined With Chemotherapy for Triple-Negative Breast CancerNot yet recruitingNCT06977542Phase 2
• A Phase II Clinical Study of Multimodal Ablation Combined With Systemic Drug Therapy for Advanced Solid Tumors.RecruitingNCT06889610Phase 2
• HIM Typing Guides the Treatment of Advanced First-Line Triple-Negative Breast CancerNot yet recruitingNCT06849492Phase 2
• Real-world Patient-reported Outcome of Sacituzumab Govitecan in Chinese Metastatic Triple-negative Breast CancerNot yet recruitingNCT06798506
• Non-Inferiority Study on MRNA-lncRNA Model in Low-Risk Triple-Negative Breast Cancer PatientsNot yet recruitingNCT06795503Phase 3
• BrAin Metastasis in TripLe Negateive Breast Cancer: IvoneScimab and Trop2 ADCRecruitingNCT06793332Phase 2
• Capecitabine in Low Risk Triple Negative Breast CancerRecruitingNCT06787339Phase 2
• QL1706 Plus Chemotherapy +/- Bevacizumab in 1L Treatment of R/mTNBCRecruitingNCT06786026Phase 2
• JAK1 Inhibitor Ivarmacitinib Reversing Immunotherapy Resistance in TNBCNot yet recruitingNCT06731153Phase 2
• Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast CancerRecruitingNCT06649331Phase 2
• All Trans Retinoic Acid Combined with Toripalimab+Chemotherapy for Locally Advanced Inoperable or Metastatic Triple Negative Breast Cancer：a Multi-center, Multi-cohort Phase II TrialRecruitingNCT06636981Phase 2
• QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Early High-Risk TNBC Breast CancerNot yet recruitingNCT06404736Phase 2
• LM-108 in Combination With PD-1 Based Treatment for Patients With Recurrent or Metastatic Triple - Negative Breast CancerRecruitingNCT06387628Phase 2
• Dasatinib Combined With Quercetin to Reverse Chemo Resistance in Triple Negative Breast CancerRecruitingNCT06355037Phase 2
• SHR-A1921 Combined With Bevacizumab in Triple-negative Breast Cancer With Brain MetastasesNot yet recruitingNCT06210438Phase 2
• A Study of Camrelizumab Plus Chemotherapy in Combination With or Without Famitinib as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (BCTOP-T-N01)RecruitingNCT05999149Phase 3
• Everolimus With Investigator's Choice of Chemotherapy in Advanced Triple-Negative Breast Cancer (TNBC) With Luminal Androgen Receptor (LAR) SubtypeRecruitingNCT05954442Phase 3
• T-DXd in the First-Line Treatment of Locally Advanced or Metastatic TNBC-LAR HER2-low PatientsNot yet recruitingNCT05953168Phase 2
• An Umbrella Trial Based on Molecular Pathway for Patients With Metastatic TNBC in First-line Treatment (FUTURE-Trop2)Not yet recruitingNCT05928780Phase 1/2
• Study of Antivascular Therapy Combined With Chemotherapy Versus Chemotherapy in Adjuvant Therapy of TNBC-BLIS Patients (BCTOP-T-A03)RecruitingNCT05909332Phase 3
• A Multi-center, Randomized, Open-label, Phase III Study Comparing PD-1 Inhibitor Combined With Antivascular Therapy and Anthracycline/Taxane-based Adjuvant Chemotherapy Versus Anthracycline/Taxane-based Adjuvant Chemotherapy Alone in Patients With Operable Triple-negative Breast CancerRecruitingNCT05862064Phase 3
• Precise Treatment for BLIS Subtype of TNBC in the First-line Treatment of Locally Advanced or Metastatic Breast CancerRecruitingNCT05806060Phase 3
• Famitinib in Combination With Camrelizumab and TPC in The First-line Treatment of Immunomodulatory Locally Advanced or Metastatic TNBC.RecruitingNCT05760378Phase 3
• FUSCC Refractory TNBC Platform Study (FUTURE2.0)RecruitingNCT05749588Phase 2
• Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant TherapyRecruitingNCT05582499Phase 2
• Reverse Triple Negative Immune Resistant Breast CancerRecruitingNCT05076682Phase 2
• Effect of Huaier Granule on Adjuvant Treatment for High-risk Early-stage Triple-negative Breast CancerRecruitingNCT04790305Phase 4
• Inosine Reverse Chemo Resistance in Triple Negative Breast CancerCompletedNCT06355024Phase 2
• A Trial Exploring the Opportune Administration of Nab-paclitaxel in the First Line Treatment, Camrelizumab Combined With Nab-paclitaxel and Famitinib, of TNBC.Status unknownNCT05670925Phase 2
• A Clinical Study of the Efficacy and Safety of Chidamide in Combination With Camrelizumab and Carboplatin or Capecitabine in the Second and Third Line Treatment of Relapsed/Metastatic Triple-negative Breast CancerStatus unknownNCT05438706Phase 2
• Induction of Cisplatin/Nab-paclitaxel/Pembrolizumab Followed by Olaparib/Pembrolizumab Maintenance in mTNBC PatientsStatus unknownNCT05174832Phase 2
• Tislelizumab in Combination With Eribulin for Patients With Metastatic Previously heaviLy-treAted TriplE-negative Breast Cancer：A Prospective Multiple-center Phase II StudyStatus unknownNCT04913571Phase 2
• Guided Treatment Based on Mini-PDX in Metastatic Triple Negative Breast CancerStatus unknownNCT04745975Phase 2
• A Phase II Study to Explore the Safety, Tolerability, and Preliminary Antitumor Activity of Sitravatinib Plus Tislelizumab or Combination With Nab-paclitaxel in Patients With Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC)Active, not recruitingNCT04734262Phase 2
• First-line Nab-paclitaxel Plus Cisplatin Plus Camrelizumab in mTNBC PatientsCompletedNCT04537286Phase 2
• Eribulin Plus Cisplatin Versus Gemcitabine Plus Cisplatin in Triple Negative Breast Cancer (TNBC)Status unknownNCT04517292Phase 2
• Neoadjuvant Dose-dense EC Followed by ABX With PD-1 for Triple Negative Breast Cancer PatientsStatus unknownNCT04418154Phase 2
• Evaluating the Clinical Value of Traditional Chinese Medicine in the Adjuvant Therapy of Triple-negative Breast CancerStatus unknownNCT04403529Phase 3
• An Umbrella Trial Based on Molecular Pathway for Patients With Metastatic TNBC.Active, not recruitingNCT04395989Phase 2
• A Study to Evaluate Gemcitabine Plus Cisplatin in the Treatment of TNBC Patients Following Neoadjuvant ChemotherapyStatus unknownNCT04297267Phase 2
• Carboplatin Intensified Chemotherapy for TRIple NEgative Breast Cancer(CITRINE)Active, not recruitingNCT04296175Phase 3
• Chidamide Combined With Cisplatin for Relapsed or Metastatic Triple-negative Breast CancerStatus unknownNCT04192903Phase 2
• A Trial of Camrelizumab in Combination With Nab-paclitaxel and Famitinib as a First Line Treatment in Patients With Unresectable Locally Advanced or Metastatic Immunomodulatory Triple Negative Breast Cancer(FUTURE-C-PLUS)Status unknownNCT04129996Phase 2
• Study Comparing Paclitaxel Plus Carboplatin Versus Anthracyclines Followed by Docetaxel as Adjuvant Chemotherapy for Triple Negative Breast Cancer (PATTERN)CompletedNCT04031703Phase 3
• FUSCC Refractory TNBC Umbrella (FUTURE)Status unknownNCT03805399Phase 1/2
• Albumin-Bound Paclitaxel Followed by Epirubicin in Combination With Cyclophosphamide in Triple Negative Breast CancerStatus unknownNCT03799679Phase 4
• PD-1(Programmed Death-1) Antibody +GP as First Line Treatment for Triple Negative Breast Cancer(TNBC) PatientsStatus unknownNCT03251313Phase 1
• Stereotactic Body Radiation Therapy Combined With Anti-PD-1 Antibody in Metastatic Triple Negative Breast CancerStatus unknownNCT03151447Phase 1
• Mutation of BRCA1/2 and Other Potential Genes in Triple-negative Breast CancerStatus unknownNCT02670668Not applicable
• TA(E)C-GP Versus A(E)C-T for the High Risk TNBC Patients and Validation of the mRNA-lncRNA SignatureActive, not recruitingNCT02641847Phase 2/3
• ABX Plus Cisplatin Versus Gemcitabine Plus Cisplatin in Triple Negative Breast Cancer (TNBC)CompletedNCT02546934Phase 3
• Bicalutamide as A Treatment in AR-positive Metastatic Triple-Negative Breast Cancer (mTNBC) PatientsTerminatedNCT02348281Phase 2
• Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Carboplatin in Triple Negative Breast Cancer (TNBC)Status unknownNCT02341911Phase 2
• Salvage Chemotherapy of Vinorelbine Plus Oxaliplatin in Metastatic Triple-negative Breast Cancer:a Prospective TrialStatus unknownNCT01528826Phase 2
• Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Paclitaxel in Triple Negative Breast Cancer (TNBC)CompletedNCT01287624Phase 3
• Adjuvant Platinum and Taxane in Triple-negative Breast Cancer (PATTERN)CompletedNCT01216111Phase 3
• Study of Apatinib in Metastatic Triple-Negative Breast Cancer PatientsCompletedNCT01176669Phase 2